Study Finds GLP-1 Drugs Reduce Long-Term Sick Leave by 17 Percent
A study using Danish data found that patients taking GLP-1 medications had 17 percent fewer long-term sick leave absences compared to those not on the drugs. The research suggests potential workforce participation and productivity benefits beyond clinical outcomes for obesity and diabetes treatment. The findings may inform Medicaid coverage decisions and utilization management policies for GLP-1s, which have been subject to state budget scrutiny due to high costs. The study did not specify implementation timelines but reflects ongoing evaluation of these drugs' broader economic impacts.
This evidence of reduced absenteeism may influence state Medicaid agencies' cost-benefit analyses for GLP-1 coverage, particularly as states weigh budget impact against potential downstream savings from improved workforce participation among beneficiaries.
Pharmacy
You might also like